<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raoul Poupon, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Lindor, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary biliary cholangitis (PBC; previously referred to as primary biliary cirrhosis) is characterized by a T-lymphocyte-mediated attack on small intralobular bile ducts. A continuous assault on the bile duct epithelial cells leads to their gradual destruction and eventual disappearance (<a class="graphic graphic_picture graphicRef79032" href="/z/d/graphic/79032.html" rel="external">picture 1</a>). The sustained loss of intralobular bile ducts causes the signs and symptoms of cholestasis and eventually may result in cirrhosis and liver failure [<a href="#rid1">1-3</a>]. The terminology was changed from primary biliary cirrhosis to primary biliary cholangitis to more accurately describe the disorder and its natural history [<a href="#rid4">4</a>]. With the advent of treatment with <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a>, the majority of patients now have normal life expectancies and only a minority of patients develops cirrhosis. (See  <a class="medical medical_review" href="/z/d/html/3616.html" rel="external">"Pathogenesis of primary biliary cholangitis (primary biliary cirrhosis)"</a>.)</p><p>This topic will review the clinical manifestations and diagnosis of PBC. It will also review factors associated with prognosis. The pathogenesis of PBC, the treatment of PBC, and the treatment of pruritus due to cholestasis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3616.html" rel="external">"Pathogenesis of primary biliary cholangitis (primary biliary cirrhosis)"</a> and  <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">"Overview of the management of primary biliary cholangitis"</a> and  <a class="medical medical_review" href="/z/d/html/3609.html" rel="external">"Liver transplantation in primary biliary cholangitis"</a> and  <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">"Pruritus associated with cholestasis"</a>.)</p><p>The American Association for the Study of Liver Diseases issued a practice guideline for PBC in 2018 [<a href="#rid5">5</a>]. The discussion that follows is generally consistent with that guideline. </p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Primary biliary cholangitis (PBC) is rare, with a reported prevalence of 19 to 402 cases per million persons [<a href="#rid6">6,7</a>]. The vast majority of patients (90 to 95 percent) are women, and most patients are diagnosed between the ages of 30 and 65 years (often in their 40s or 50s), though the disease has been reported in women as young as 15 years and as old as 93 years [<a href="#rid8">8-10</a>]. </p><p>The incidence of PBC developing in a well-defined population from Rochester, Minnesota was estimated to be 2.7 per 100,000 person-years (4.5 per 100,000 person-years for women and 0.7 per 100,000 person-years for men) [<a href="#rid6">6</a>]. The age and sex-adjusted prevalences per 100,000 persons were 65.4 for women and 12.1 for men.</p><p>PBC prevalence appears to vary geographically and is most common in northern Europe and North America (particularly in Scandinavia, Great Britain, and the northern midwest regions of the United States) [<a href="#rid11">11</a>]. However, one study found that disease severity was higher in Black and Hispanic Americans for reasons that were unclear [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/3616.html" rel="external">"Pathogenesis of primary biliary cholangitis (primary biliary cirrhosis)", section on 'Clues about etiology based on the epidemiology of PBC'</a>.)</p><p>Studies suggest that the disease burden from PBC is increasing over time:</p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based study from the United Kingdom, the incidence rose from 23 cases per million in 1987 to 32 cases per million in 1994 [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2004 study from Victoria, Australia found that the prevalence was 51 cases per million-population, compared with 10 cases per million-population in 1991 [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2009 study from Canada estimated that the overall age and sex-adjusted annual incidence was 30.3 cases per million (48.4 per million women and 10.4 per million men) [<a href="#rid14">14</a>]. While the incidence had not changed between 1996 and 2002, the prevalence increased from 100 to 227 per million.</p><p></p><p>One possible explanation for the increase in disease burden is better detection and increased awareness of PBC, rather than a true change in disease incidence. </p><p>Familial clustering of PBC has also been noted, suggesting genetic susceptibility in some patients. The prevalence of PBC is 100 times higher in first-degree relatives of a patient with PBC compared with the general population. Allelic variations in MHC class II (DR, DQ) and in components of the innate and adaptive immune systems have been associated with susceptibility to PBC [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/3616.html" rel="external">"Pathogenesis of primary biliary cholangitis (primary biliary cirrhosis)", section on 'Genetic susceptibility'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with primary biliary cholangitis (PBC) may be asymptomatic, or they may present with symptoms such as fatigue and pruritus. Other clinical manifestations include jaundice, cholestatic liver enzymes, antimitochondrial antibodies, and signs and symptoms of cirrhosis.</p><p class="headingAnchor" id="H58137725"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Approximately 50 to 60 percent of patients with PBC are asymptomatic at diagnosis and are detected because of abnormalities in liver biochemical tests obtained for other reasons [<a href="#rid16">16-18</a>]. Among patients with symptoms, fatigue and pruritus are most commonly seen (<a class="graphic graphic_table graphicRef50201" href="/z/d/graphic/50201.html" rel="external">table 1</a>). In newly diagnosed patients, approximately one-half complain of fatigue and one-third pruritus [<a href="#rid8">8</a>]. In addition, patients may have signs and symptoms due to associated autoimmune disorders or from complications of PBC, such as cirrhosis. (See <a class="local">'Associated autoimmune conditions'</a> below and <a class="local">'Complications'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fatigue </strong>– In patients with PBC, fatigue is associated with excessive daytime somnolence and can be a major factor that impairs quality of life [<a href="#rid19">19-22</a>]. It may have several contributing causes, although it does not appear to be explained by depression [<a href="#rid23">23,24</a>]. One report suggested that fatigue remains fairly constant over time in individual patients and that it may be associated with decreased survival [<a href="#rid25">25</a>]. Another report found that fatigue correlated with muscle mitochondrial dysfunction manifested as excessive acidosis after exercise [<a href="#rid26">26</a>]. An association with autonomic dysfunction has also been reported [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pruritus </strong>– Pruritus has been reported by 20 to 70 percent of patients and often precedes the development of jaundice [<a href="#rid11">11</a>]. It may initially develop during pregnancy and be mistaken for intrahepatic cholestasis of pregnancy. However, the latter disorder resolves in the postpartum period, whereas that due to PBC typically persists. Itching is worse at night, under constricting or coarse garments, in association with dry skin, and in hot, humid weather. (See  <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">"Pruritus associated with cholestasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other signs and symptoms </strong>– Patients with PBC may report right upper quadrant discomfort, which was noted by 8 percent of patients in one study [<a href="#rid28">28</a>]. Impairment in memory and concentration has also been reported in patients with PBC. In one study, these features were present in 53 percent of 198 patients with PBC [<a href="#rid29">29</a>]. They correlated with the presence of structural brain lesions and autonomic dysfunction, but did not correlate with the severity of liver disease. Patients with advanced PBC may develop malabsorption and steatorrhea and may have with findings associated with fat-soluble vitamin deficiencies (<a class="graphic graphic_table graphicRef76166" href="/z/d/graphic/76166.html" rel="external">table 2</a>).</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The findings on physical examination in patients with PBC vary widely and depend on the stage of the disease at time of presentation. The physical examination is often normal in patients who are asymptomatic. Skin findings are common, such as hyperpigmentation, excoriations, xanthelasmas, and jaundice. Patients may also have hepatosplenomegaly or examination findings suggestive of cirrhosis (<a class="graphic graphic_table graphicRef90943" href="/z/d/graphic/90943.html" rel="external">table 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin </strong>– Skin findings in patients with PBC may include hyperpigmentation, jaundice, xanthomas (<a class="graphic graphic_picture graphicRef75143 graphicRef57793" href="/z/d/graphic/75143.html" rel="external">picture 2A-B</a>), xanthelasmas (<a class="graphic graphic_picture graphicRef67919" href="/z/d/graphic/67919.html" rel="external">picture 3</a>), xerosis (dry skin), dermatographism, and fungal infections of the feet or nails. The skin may initially be normal, but excoriations from scratching due to pruritus may be severe enough to cause bleeding and may occur as the disease progresses. In one study, 40 percent of patients with PBC presented with a dermatologic complaint [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1">Approximately 25 to 50 percent of newly diagnosed patients have hyperpigmentation of skin [<a href="#rid30">30</a>]. This change is due to melanin deposition, not jaundice [<a href="#rid31">31,32</a>]. The cause is unknown, but similar findings occur in other types of chronic liver disease, such as hemochromatosis. </p><p></p><p class="bulletIndent1">Jaundice is typically a later manifestation of the disease, but may be seen at presentation in some patients. Xanthomas from hyperlipidemia are also late manifestations that occur in less than 5 percent of patients. Xanthelasmas are more common and occur in approximately 10 percent of patients. (See  <a class="medical medical_review" href="/z/d/html/3602.html" rel="external">"Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatosplenomegaly </strong>–<strong> </strong>Striking hepatic enlargement is often found in patients with PBC and may be detected in asymptomatic patients. Hepatomegaly becomes more common as the disease progresses [<a href="#rid33">33</a>]. The frequency with which splenomegaly is present on initial presentation has not been well described. However, it appears to be decreasing, probably because PBC is being diagnosed in earlier stages than in the past. Splenomegaly becomes more common as PBC progresses and usually is a sign of portal hypertension. (See  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Splenomegaly'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other findings –</strong> Spider nevi, temporal and proximal limb muscle wasting, ascites, and edema are all late manifestations of disease and suggest cirrhosis (<a class="graphic graphic_table graphicRef90943" href="/z/d/graphic/90943.html" rel="external">table 3</a>). Kayser-Fleischer rings are a very rare manifestation and result from copper retention [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Physical examination'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Common laboratory test abnormalities in patients with PBC included an elevated alkaline phosphatase, antimitochondrial antibodies (AMA), antinuclear antibodies (ANA), and hyperlipidemia. Other findings may include mild elevations in the aminotransferases and an elevated bilirubin level.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver biochemical and function tests </strong>– The serum alkaline phosphatase concentration is almost always elevated in PBC, often to striking levels, and is of hepatic origin. Serum aminotransferases may be normal or slightly elevated. The serum bilirubin concentration is usually normal early in the course of the disease, but becomes elevated in most patients as the disease progresses [<a href="#rid35">35</a>]. Both the direct and indirect fractions are increased. An elevated serum bilirubin is a poor prognostic sign [<a href="#rid35">35</a>]. (See <a class="local">'Prognostic factors'</a> below.)</p><p></p><p class="bulletIndent1">The alkaline phosphatase value tends to reach a plateau early in the course of the disease and then usually fluctuates within 20 percent of this value [<a href="#rid36">36</a>]. Serum levels of 5'-nucleotidase and gamma-glutamyl transpeptidase parallel those of alkaline phosphatase. (See  <a class="medical medical_review" href="/z/d/html/3612.html" rel="external">"Enzymatic measures of hepatic cholestasis (alkaline phosphatase, 5'-nucleotidase, gamma-glutamyl transpeptidase)"</a>.)</p><p></p><p class="bulletIndent1">If elevated, the serum levels of aminotransferases are rarely increased more than fivefold above normal. They tend to fluctuate within a relatively narrow range. When they are five times normal or higher, the overlap syndrome (PBC plus autoimmune hepatitis) should be considered. (See  <a class="medical medical_review" href="/z/d/html/3636.html" rel="external">"Autoimmune hepatitis variants: Definitions and treatment", section on 'Autoimmune hepatitis-PBC overlaps'</a>.)</p><p></p><p class="bulletIndent1">Additional abnormalities that may be seen in patients who have developed cirrhosis include a low serum albumin and an elevated international normalized ratio (INR).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologic abnormalities </strong>– Patients with PBC may have iron deficiency anemia due to gastrointestinal blood loss related to portal hypertension. Patients with cirrhosis may also have thrombocytopenia and leukopenia (<a class="graphic graphic_table graphicRef90943" href="/z/d/graphic/90943.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">"Portal hypertension in adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">Increased numbers of eosinophils have been demonstrated in the blood and liver of patients with PBC, particularly in its early stages, suggesting that they may have a pathogenic role [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serologic markers:</strong> AMA are present in almost all patients with PBC. ANA are also common and found in up to 70 percent of patients with PBC </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antimitochondrial antibodies </strong>– AMA are the serologic hallmark of PBC. They are present in approximately 95 percent of patients with PBC. (See  <a class="medical medical_review" href="/z/d/html/3616.html" rel="external">"Pathogenesis of primary biliary cholangitis (primary biliary cirrhosis)", section on 'Antimitochondrial antibodies'</a>.)</p><p></p><p class="bulletIndent2">Occasionally, AMA are detected in patients with no other features suggestive of PBC. Many of these patients will eventually go on to develop features of PBC. (See <a class="local">'Positive AMA'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antinuclear antibodies </strong>– ANA are found in up to 70 percent of patients with PBC [<a href="#rid39">39-44</a>]. A variety of staining patterns may be present. Two immunofluorescence patterns are considered "PBC-specific": the multiple nuclear dots pattern (target antigen, Sp100) and the rim-like/membranous pattern (target antigens, gp210, nucleoporin p62, and the lamin B receptor). Other antibodies such as anticentromere, anti-SSA/Ro, and anti-dsDNA antibodies can be also found in PBC.</p><p></p><p class="bulletIndent2">ANA have clinical significance in PBC for two reasons. First, their presence can cause confusion with autoimmune hepatitis or autoimmune hepatitis/PBC overlap. Second, some suggest that ANA may be associated with more rapid progression of disease and a poorer prognosis [<a href="#rid42">42,45-47</a>]. However, the strength of this association and the implications for management are uncertain. For example, patients with PBC who are AMA-negative and have a positive ANA, a disease often called autoimmune cholangitis but more appropriately AMA-negative PBC, have the same outcomes as those who are AMA-positive and ANA-negative. (See  <a class="medical medical_review" href="/z/d/html/3636.html" rel="external">"Autoimmune hepatitis variants: Definitions and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum lipids </strong>– Serum lipids may be strikingly elevated in PBC. Serum cholesterol levels are elevated in at least 50 percent of patients, and may exceed 1000 mg/dL (26 mmol/L) in patients with xanthomas [<a href="#rid48">48</a>]. Patients with early PBC often have mild elevations of low-density and very-low-density lipoproteins (LDL and VLDL) and striking elevations of high-density lipoproteins (HDL) [<a href="#rid49">49</a>]. This may explain why patients with PBC, despite striking hypercholesterolemia, do not appear to be at increased risk of death from atherosclerosis. (See  <a class="medical medical_review" href="/z/d/html/3602.html" rel="external">"Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other abnormalities </strong>– Other biochemical abnormalities in PBC include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased serum concentrations of immunoglobulin M (IgM), ceruloplasmin, bile acids (which are strikingly elevated) [<a href="#rid50">50</a>], and hyaluronate [<a href="#rid51">51</a>]. Rising hyaluronate levels correlate with the serum bilirubin and histologic worsening of the disease [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antithyroid antibodies are often seen in patients with PBC, though they are not always associated with clinically apparent thyroid disease [<a href="#rid52">52</a>]. (See <a class="local">'Associated autoimmune conditions'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with PBC who develop cirrhosis may have hyponatremia or elevated serum creatine levels (<a class="graphic graphic_table graphicRef90943" href="/z/d/graphic/90943.html" rel="external">table 3</a>). </p><p></p><p class="headingAnchor" id="H58138901"><span class="h2">Associated autoimmune conditions</span><span class="headingEndMark"> — </span>Patients with PBC are often diagnosed with other autoimmune disorders, including Sjögren's disease and autoimmune thyroid disease (<a class="graphic graphic_table graphicRef50201" href="/z/d/graphic/50201.html" rel="external">table 1</a>). Musculoskeletal complaints, frequently due to an inflammatory arthropathy, occur in approximately 40 percent of patients with PBC (with some estimates as high as 70 percent) [<a href="#rid53">53</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 40 to 65 percent of patients have symptoms of Sjögren's disease, including keratoconjunctivitis (dry eyes) and/or xerostomia (dry mouth) [<a href="#rid54">54,55</a>]. These clinical features usually precede those directly associated with PBC. On the other hand, PBC is an uncommon development in patients with primary Sjögren's disease [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease"</a> and  <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">"Clinical manifestations of Sjögren's disease: Exocrine gland disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid disease occurs in 10 to 15 percent of patients with PBC [<a href="#rid57">57,58</a>]. The most common form is Hashimoto's thyroiditis. Clinical manifestations of Hashimoto's thyroiditis include development of a goiter and symptoms of hypothyroidism (<a class="graphic graphic_table graphicRef62676" href="/z/d/graphic/62676.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/7854.html" rel="external">"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)", section on 'Clinical phenotypes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 5 to 15 percent of patients with PBC have limited cutaneous scleroderma, which is frequently associated with anticentromere antibodies and may include the CREST syndrome (Calcinosis cutis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) [<a href="#rid53">53,59</a>]. In approximately one-half of these individuals, the symptoms of scleroderma occur prior to those of PBC. Clonal expansion of T-cells bearing a specific beta chain variable region (TCRBV3) has been demonstrated in some of these patients, suggesting that patients with PBC and CREST syndrome may have a distinct disorder [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Classic rheumatoid arthritis develops in 5 to 10 percent of patients with PBC, while the "arthritis of PBC" is observed in another 10 percent [<a href="#rid60">60,61</a>]. The latter disorder is characterized by a transient nondeforming rheumatoid-factor negative synovitis involving one or more peripheral joints [<a href="#rid60">60</a>]. These manifestations are similar to those of hypercholesterolemic arthropathy [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/7502.html" rel="external">"Clinical manifestations of rheumatoid arthritis"</a>.)</p><p></p><p class="headingAnchor" id="H58139388"><span class="h2">Complications</span></p><p class="headingAnchor" id="H58139427"><span class="h3">Cirrhosis</span><span class="headingEndMark"> — </span>Patients with PBC that has progressed to cirrhosis have clinical manifestations similar to those seen with other forms or cirrhosis, including nonspecific symptoms (eg, anorexia, weight loss, weakness, fatigue) or signs and symptoms of hepatic decompensation (jaundice, pruritus, signs of upper gastrointestinal bleeding, abdominal distension from ascites, confusion due to hepatic encephalopathy) (<a class="graphic graphic_table graphicRef90943" href="/z/d/graphic/90943.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>In patients with PBC, esophageal varices may develop prior to the development of other signs of cirrhosis, possibly because of presinusoidal inflammation and subsequent fibrosis induced by granulomas [<a href="#rid11">11</a>]. The other complications of portal hypertension (eg, ascites, hepatic encephalopathy) are typically seen with end-stage cirrhosis. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Major complications'</a>.)</p><p class="headingAnchor" id="H58141811"><span class="h3">Hepatocellular carcinoma</span><span class="headingEndMark"> — </span>Patients with PBC and cirrhosis are at increased risk for hepatocellular carcinoma (HCC) [<a href="#rid63">63-67</a>]. A meta-analysis of 17 studies found that patients with PBC had a higher risk of HCC compared with the general population (relative risk 19; 95% CI 11-27) [<a href="#rid68">68</a>]. In a large cohort study including more than 4500 patients with PBC, the incidence of HCC was 0.34 per 100-patient-years [<a href="#rid67">67</a>]. In a multivariable analysis including only patients who were treated with UDCA for at least 12 months, risk factors for HCC were biochemical nonresponse (adjusted HR 3.44, 95% CI 1.65-7.14) and thrombocytopenia (adjusted HR 1.42, 95% CI 1.10-1.74). </p><p>The approach to surveillance for HCC in high-risk patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults"</a>.)</p><p class="headingAnchor" id="H58139488"><span class="h3">Metabolic bone disease</span><span class="headingEndMark"> — </span>Patients with PBC are at risk for metabolic bone disease, including osteopenia and osteoporosis, which are the characteristic bone disorders in PBC and may reflect the inhibitory effect of a retained toxin on the osteoblast. Rarely, patients develop osteomalacia, which is characterized by decreased bone mineralization, bone pain, and fractures. Metabolic bone disease in patients with primary biliary cholangitis is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3606.html" rel="external">"Evaluation and treatment of low bone mass in primary biliary cholangitis (primary biliary cirrhosis)"</a>.)</p><p class="headingAnchor" id="H58140160"><span class="h3">Other complications</span><span class="headingEndMark"> — </span>Patients with advanced PBC may develop malabsorption and steatorrhea, which in turn can lead to deficiencies of fat-soluble vitamins (<a class="graphic graphic_table graphicRef76166" href="/z/d/graphic/76166.html" rel="external">table 2</a>) [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H58140621"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H54228114"><span class="h2">When to consider PBC</span><span class="headingEndMark"> — </span>Primary biliary cholangitis (PBC) should be considered in patients with an elevated alkaline phosphatase without extrahepatic biliary obstruction, and in women with unexplained itching, fatigue, jaundice, or unexplained weight loss with right upper quadrant discomfort. PBC is more likely if the patient has signs and symptoms suggestive of associated disorders. Patients should be questioned about symptoms of diseases such as Sjögren's disease (dry eyes and mouth), arthritis, and Raynaud phenomenon. (See  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a>.)</p><p class="headingAnchor" id="H58141317"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>A diagnosis of PBC is established if there is no extrahepatic biliary obstruction, no comorbidity affecting the liver, and at least two of the following are present [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An alkaline phosphatase at least 1.5 times the upper limit of normal</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of antimitochondrial antibodies (AMA) at a titer of 1:40 or higher (or other PBC specific autoantibodies [sp100 or gp210], if AMA is negative) (see <a class="local">'Laboratory tests'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histologic evidence of PBC (nonsuppurative destructive cholangitis and destruction of interlobular bile ducts)</p><p></p><p>While a liver biopsy is often not required to make the diagnosis, it provides useful information with regard to staging and prognosis. (See <a class="local">'Liver biopsy'</a> below.)</p><p class="headingAnchor" id="H58140932"><span class="h2">Diagnostic approach</span><span class="headingEndMark"> — </span>Patients suspected of having PBC based on the presence of an elevated alkaline phosphatase with or without suggestive symptoms should undergo the following evaluation (<a class="graphic graphic_algorithm graphicRef140937" href="/z/d/graphic/140937.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Imaging to exclude extrahepatic biliary obstruction (typically a right upper quadrant ultrasound or magnetic resonance cholangiopancreatography, or if the suspicion for obstruction is high, endoscopic retrograde cholangiopancreatography). (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Extrahepatic cholestasis'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assay for AMA if extrahepatic biliary obstruction is excluded. Most assays are 95 percent sensitive and 98 percent specific for PBC [<a href="#rid69">69</a>]. An exception is tests using indirect immunofluorescence, which are operator dependent and have been associated with false-positive and false-negative results. (See  <a class="medical medical_review" href="/z/d/html/3616.html" rel="external">"Pathogenesis of primary biliary cholangitis (primary biliary cirrhosis)", section on 'Antimitochondrial antibodies'</a>.)</p><p></p><p>Additional testing depends on the results of the initial evaluation: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated alkaline phosphatase, positive AMA, clinical picture suggestive of PBC </strong>– If the alkaline phosphatase is at least 1.5 times the upper limit of normal, the AMA is positive with a titer of at least 1:40, and the clinical picture is suggestive of PBC (eg, the patient is female and does not have any comorbidities that might affect the liver), additional diagnostic testing is not needed. However, a liver biopsy may help stage the disease and provide useful prognostic information. (See <a class="local">'Liver biopsy'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated alkaline phosphatase, positive AMA, clinical picture inconsistent with PBC </strong>–<strong> </strong>If the alkaline phosphatase is elevated and the AMA is positive, but elements of the clinical picture are not suggestive of PBC (eg, the patient is male or has comorbidities such as overweight, diabetes, or systemic disease that might affect the liver), we confirm the diagnosis with a liver biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated alkaline phosphatase, negative AMA </strong>– If the alkaline phosphatase is elevated but the AMA is negative, alternative diagnoses should be considered. A liver biopsy should be obtained if additional noninvasive testing does not yield an alternative diagnosis. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Intrahepatic cholestasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal alkaline phosphatase, positive AMA </strong>– If the AMA is positive but the alkaline phosphatase is normal, a liver biopsy is not required if the suspicion for PBC is high. However, if the diagnosis is in doubt or if a definitive diagnosis is required, a liver biopsy should be obtained. (See <a class="local">'Liver biopsy'</a> below and <a class="local">'Positive AMA'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal alkaline phosphatase, negative AMA </strong>– If the alkaline phosphatase is normal and the AMA is negative, a diagnosis of PBC is excluded and additional causes for the patient’s symptoms should be sought. (See  <a class="medical medical_review" href="/z/d/html/2783.html" rel="external">"Approach to the adult patient with fatigue"</a> and  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H58140687"><span class="h2">Liver biopsy</span><span class="headingEndMark"> — </span>While a liver biopsy is often not required to make the diagnosis of PBC, it may provide useful information with regard to staging and prognosis [<a href="#rid70">70</a>]. However, not all centers perform routine liver biopsies, reserving them for cases of diagnostic uncertainty or when determining the stage of disease will change management decisions. Our practice is to obtain a liver biopsy if the diagnosis is in doubt, the patient also has evidence of autoimmune hepatitis (eg, a high serum ALT, anti-smooth muscle antibodies), or if the patient does not respond optimally to therapy with <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a>. (See <a class="local">'Prognostic factors'</a> below and  <a class="medical medical_review" href="/z/d/html/3586.html" rel="external">"Transjugular liver biopsy", section on 'Indications and contraindications'</a> and  <a class="medical medical_review" href="/z/d/html/3665.html" rel="external">"Overview of autoimmune hepatitis", section on 'Patterns of clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/3587.html" rel="external">"Approach to liver biopsy"</a> and  <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">"Overview of the management of primary biliary cholangitis", section on 'Initial therapy'</a>.)</p><p>The pathognomonic florid bile duct lesion is uncommonly seen in percutaneous needle biopsies of the liver (<a class="graphic graphic_picture graphicRef54128 graphicRef66904 graphicRef53861" href="/z/d/graphic/54128.html" rel="external">picture 4A-C</a>). However, the greater the number of portal triads in the specimen, the more likely it is that these lesions and granulomas will be present. The continuous assault on the bile duct epithelial cells leads to their gradual destruction and eventual disappearance. The hepatocyte injury is associated with foamy degeneration, which is thought to be due to the toxic effect of retained bile acids (<a class="graphic graphic_picture graphicRef65727" href="/z/d/graphic/65727.html" rel="external">picture 5</a>).</p><p>Histologic findings in PBC are often staged on a scale of zero to four (see  <a class="medical medical_review" href="/z/d/html/15756.html" rel="external">"Interpretation of nontargeted liver biopsy findings in adults", section on 'Biliary tree injury'</a> and  <a class="medical medical_review" href="/z/d/html/3635.html" rel="external">"Histologic scoring systems for chronic liver disease", section on 'Primary biliary cholangitis'</a>) [<a href="#rid71">71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 0: Normal liver</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 1: Inflammation and/or abnormal connective tissue confined to the portal areas</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 2: Inflammation and/or fibrosis confined to portal and periportal areas</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 3: Bridging fibrosis</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 4: Cirrhosis</p><p></p><p class="headingAnchor" id="H58140968"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H58141653"><span class="h2">Cholestasis</span><span class="headingEndMark"> — </span>The differential diagnosis of primary biliary cholangitis (PBC) includes other causes of cholestasis. Findings that suggest a diagnosis of PBC include skin hyperpigmentation, pruritus, a positive antimitochondrial antibody (AMA), and hypercholesterolemia. Other diagnoses are more likely in patients who are male and in patients who are &lt;30 years old or &gt;65 years old. </p><p>Other causes of cholestasis include [<a href="#rid72">72</a>] (see  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Elevated alkaline phosphatase'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Bile duct obstruction from gallstones or malignancy</p><p class="bulletIndent1"><span class="glyph">●</span>Primary sclerosing cholangitis (PSC), IgG4-related disease</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced cholestasis</p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial, fungal, and viral infections</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic amyloidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphoma and solid organ malignancies</p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac diseases</p><p class="bulletIndent1"><span class="glyph">●</span>Intrahepatic cholestasis of pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>Total <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a></p><p class="bulletIndent1"><span class="glyph">●</span>Viral hepatitis</p><p></p><p>Patients should be questioned about the use of medications, some of which may cause cholestasis similar to that of PBC. Among the most common drugs that cause cholestasis are phenothiazines, synthetic androgenic steroids, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and in our experience, <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a>, <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>, and <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>. The likelihood of drug-induced cholestasis is higher if the patient is taking an offending agent and the clinical picture is inconsistent with PBC (eg, the patient is AMA-negative or male). However, differentiating between drug-induced cholestasis and PBC if the clinical features are consistent with both disorders can be difficult. Liver biopsy may not help make the diagnosis because the histologic findings of chronic cholestasis injury due to drug use are similar to those of PBC. In cases where it is unclear, we reevaluate the patient with laboratory testing and liver imaging after stopping the drug for three months. (See  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a> and <a class="local">'Diagnosis'</a> above.)</p><p>Bile duct obstruction is suggested if the patient has the acute onset of jaundice or right upper quadrant pain or if the aminotransferases are moderately elevated. It should also be considered in patients with painless jaundice and no other symptoms suggestive of PBC. It is ruled out by biliary imaging. Typically, this is done with a right upper quadrant ultrasound, magnetic resonance cholangiopancreatography (MRCP), or if suspicion for a common bile duct obstruction is high, endoscopic retrograde cholangiopancreatography (ERCP). A bile duct obstruction is likely if there is intra- or extrahepatic ductal dilation, if a mass is seen, or if an obstruction is seen on cholangiography. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Extrahepatic cholestasis'</a>.)</p><p>PSC should be considered if the patient does not have extrahepatic biliary obstruction and is AMA-negative. PSC is typically diagnosed with cholangiography (MRCP or ERCP). In patients with small duct PSC (the form most likely to resemble PBC), cholangiography is normal and a liver biopsy is needed to make the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p>Patients with viral hepatitis occasionally present with cholestasis, though they typically also have aminotransferase elevations. Testing for hepatitis A, B, C, and E virus should be performed if there is no evidence of extrahepatic biliary obstruction and if the AMA is negative. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Intrahepatic cholestasis'</a>.)</p><p>Other causes of cholestasis are suggested by the history, physical examination, and absence of AMA. (See  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy", section on 'Clinical findings'</a> and  <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis", section on 'Hepatic'</a> and  <a class="medical medical_review" href="/z/d/html/3615.html" rel="external">"Classification and causes of jaundice or asymptomatic hyperbilirubinemia", section on 'Parenteral nutrition'</a>.)</p><p class="headingAnchor" id="H58141696"><span class="h2">Positive AMA</span><span class="headingEndMark"> — </span>A positive AMA may be seen in patients with features of autoimmune hepatitis or in patients who have no other signs of PBC. </p><p>Laboratory abnormalities suggestive of autoimmune hepatitis include elevated transaminases (usually higher than are seen with PBC), increased total immunoglobulin G (IgG) or gammaglobulin levels, and serologic markers (antinuclear antibodies, antismooth muscle antibodies, anti-liver-kidney microsome-1 antibodies, or anti-liver cytosol antibody-1). On biopsy, patients with autoimmune hepatitis have interface hepatitis. (See  <a class="medical medical_review" href="/z/d/html/3665.html" rel="external">"Overview of autoimmune hepatitis"</a>.)</p><p>A variant of autoimmune hepatitis with characteristics of both autoimmune hepatitis and PBC has also been described. These patients have histologic and biochemical features of both disorders (eg, positive AMA, interface hepatitis on biopsy). (See  <a class="medical medical_review" href="/z/d/html/3636.html" rel="external">"Autoimmune hepatitis variants: Definitions and treatment", section on 'Autoimmune hepatitis-PBC overlaps'</a>.)</p><p>Some patients are found to have AMA without other evidence of PBC. One study suggested that the presence of AMA alone was a predictor of the eventual development of PBC [<a href="#rid73">73</a>]. The study focused on 29 patients who had AMA, but were asymptomatic and had normal liver function. Liver biopsy revealed mild changes that were nondiagnostic, but consistent with very early PBC in 24 of 29. At 10 years, symptoms of PBC were present in 76 percent and laboratory signs of cholestasis in 83 percent. Repeat liver biopsy was performed in 10 of the patients. The disease had progressed from stage I to II in two patients and from stage I to III in two. There was no histologic progression in six patients. In a second study, the five-year incidence of PBC in AMA-positive patients with initially normal alkaline phosphatase levels was only 16 percent [<a href="#rid74">74</a>].</p><p class="bulletIndent2">Approximately 13 percent of first-degree relatives of patients with PBC have AMA, suggesting they are susceptible to developing PBC [<a href="#rid75">75</a>]. Whether the early detection of such individuals has a clinical benefit remains to be determined.</p><p></p><p class="headingAnchor" id="H54228877"><span class="h2">Fatigue and pruritus</span><span class="headingEndMark"> — </span>There are numerous causes of fatigue and pruritus other than PBC. The approaches to patients presenting with these complaints are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2783.html" rel="external">"Approach to the adult patient with fatigue"</a> and  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of primary biliary cholangitis (PBC) has improved markedly with treatment with <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a> (UDCA). Many patients with early-stage PBC may have a normal life expectancy. Studies of patients treated with UDCA have suggested a good prognosis in patients initially diagnosed with mild disease who achieve a biochemical response to UDCA. (See  <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">"Overview of the management of primary biliary cholangitis"</a>.)</p><p class="headingAnchor" id="H58142105"><span class="h2">Predictive models</span><span class="headingEndMark"> — </span>Several predictive models based upon laboratory and clinical data have been proposed, and two such models (GLOBE score and UK-PBC score) that were developed in the era of UDCA therapy are based on multicenter studies including large cohorts of patients with PBC [<a href="#rid5">5,76,77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>GLOBE score</strong> – The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.globalpbc.com%2Fglobe&amp;token=Gwu1MUQ97eeN9vbOgDEV61OEN5KOKGRXTxjOhhv8xZh2ZDfqH2jjbIN1wJrftDXv&amp;TOPIC_ID=3621" target="_blank">GLOBE score</a> includes the following five variables: serum bilirubin, albumin, alkaline phosphatase, platelet count after one year of UDCA treatment, and age at start of therapy. The GLOBE score estimates the duration of transplant-free survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>UK-PBC score</strong> – The UK-PBC score includes serum alkaline phosphatase, aminotransferases, and bilirubin after 12 months of UDCA therapy, in addition to baseline albumin and platelet count. This model estimates the risk of liver transplantation or liver-related death.</p><p></p><p class="headingAnchor" id="H58142111"><span class="h2">Prognostic factors</span><span class="headingEndMark"> — </span>Treatment with UDCA has been associated with improved outcomes in patients with PBC. Factors that have been associated with a worse prognosis include presence of symptoms at the time of diagnosis, elevated alkaline phosphatase and bilirubin levels, more advanced histologic stage, presence of antinuclear antibodies, cigarette smoking, and certain genetic polymorphisms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment with </strong><a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a><strong> </strong>–<strong> </strong>Patients treated with UDCA who were initially diagnosed with mild disease and achieve a biochemical response to UDCA have a better prognosis than those with more advanced disease or those who fail to achieve a biochemical response to UDCA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms and associated disorders </strong>–<strong> </strong>Some studies have suggested that patients with PBC who are asymptomatic at diagnosis may have a better prognosis than those who have symptoms (such as fatigue), but the strength of this association is uncertain [<a href="#rid16">16,18,78-81</a>]. Other studies have suggested that patients who have coexisting disorders related to PBC such as thyroiditis, sicca syndrome, and scleroderma also have a worse prognosis, even if they do not have symptoms more classically related to PBC [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1">It is possible that the better prognosis reported in asymptomatic patients in some studies reflects lead-time bias (ie, that such patients were detected earlier in the course of their disease). Symptoms develop in two to four years in the majority of asymptomatic patients [<a href="#rid16">16</a>], although approximately one-third may remain symptom-free for many years [<a href="#rid79">79</a>]. There is no reliable way to predict which patients will develop symptoms [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alkaline phosphatase and bilirubin level </strong>– Alkaline phosphatase and bilirubin levels are associated with transplant-free survival. In a meta-analysis of individual data of 15 studies with 4845 patients, increased alkaline phosphatase and bilirubin levels one year after study enrollment were associated with worse outcomes [<a href="#rid82">82</a>]. As an example, an alkaline phosphatase level &gt;2 times the upper limit of normal was associated with decreased 10-year transplant-free survival compared with an alkaline phosphatase level ≤2 times the upper limit of normal (62 versus 84 percent). Similarly, a bilirubin level &gt;1 times the upper limit of normal was associated with lower 10-year transplant-free survival compared with a bilirubin level ≤1 times the upper limit of normal (41 versus 86 percent). The association of alkaline phosphatase and bilirubin levels with transplant-free survival was seen with both patients who had received <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a> and those who had not.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic stage </strong>–<strong> </strong>PBC is classified histologically into four stages. (See <a class="local">'Liver biopsy'</a> above.)</p><p></p><p class="bulletIndent1">As noted above, the natural history of PBC involves histologic progression along these stages, though treatment with UDCA may slow disease progression. In a study involving 916 biopsy specimens from 222 patients followed in the pre-UDCA era, cirrhosis developed within four years in 31 and 50 percent who presented initially with stage I or II disease, respectively [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1">The presence of cirrhosis (stage IV) is associated with a worse prognosis and identifies a group of patients at risk for development of complications related to cirrhosis, including variceal bleeding and development of hepatocellular carcinoma [<a href="#rid84">84,85</a>]. In a study of 256 patients seen in the pre-UDCA era, 31 percent developed esophageal varices during a median of 5.6 years of follow-up [<a href="#rid63">63</a>]. One- and three-year survival rates were 83 and 59 percent, respectively, after the development of varices. </p><p></p><p class="bulletIndent1">In another study, the presence of ductopenia on a baseline liver biopsy predicted histologic progression despite UDCA [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serologic markers </strong>–<strong> </strong>The presence of antinuclear antibodies (in particular, antiGp210, antiSp100, and anticentromere antibodies) may identify a subgroup of patients at increased risk for progressing to liver failure [<a href="#rid42">42,45-47</a>]. (See <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent1">Patients with antimitochondrial antibody (AMA)-negative PBC are thought to have a similar clinical course and response to treatment as patients with AMA-positive PBC [<a href="#rid87">87,88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cigarette smoking </strong>–<strong> </strong>An association between PBC and cigarette smoking has been suggested in epidemiologic studies [<a href="#rid89">89</a>]. At least two studies also suggested that cigarette smoking is associated with more advanced fibrosis stage [<a href="#rid90">90,91</a>]. In one of the studies, never-smokers were significantly less likely to have advanced fibrosis (METAVIR fibrosis score of 3 or 4) (<a class="graphic graphic_table graphicRef98097" href="/z/d/graphic/98097.html" rel="external">table 5</a>) than patients who had smoked in the past or were current smokers (16 versus 33 percent) [<a href="#rid91">91</a>]. For each pack-year increase in smoking, there was a 5 percent increase in the likelihood of advanced fibrosis. (See  <a class="medical medical_review" href="/z/d/html/3635.html" rel="external">"Histologic scoring systems for chronic liver disease", section on 'Primary biliary cholangitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic variants </strong>–<strong> </strong>Certain polymorphisms of genes involved in immunity (SLCA2 [exchanger anion, AE2] and TNF-alpha) were associated with prognosis and response to UDCA therapy in a study of 258 patients [<a href="#rid92">92</a>]. More studies are needed to understand the relevance of these observations to natural history models or the choice of therapy. (See  <a class="medical medical_review" href="/z/d/html/2900.html" rel="external">"Basic genetics concepts: DNA regulation and gene expression", section on 'Implications for medicine'</a>.)</p><p></p><p class="headingAnchor" id="H303977122"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112041.html" rel="external">"Society guideline links: Primary biliary cholangitis"</a>.)</p><p class="headingAnchor" id="H100882634"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83040.html" rel="external">"Patient education: Primary biliary cholangitis (primary biliary cirrhosis) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Primary biliary cholangitis (PBC) is rare, with a reported prevalence of 19 to 402 cases per million persons. The vast majority of patients (90 to 95 percent) are female, and most patients are diagnosed between the ages of 30 and 65 years (often in their 40s or 50s), though the disease has been reported in females as young as 15 years and as old as 93 years. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– Patients with PBC may be asymptomatic, or they may present with symptoms such as fatigue and pruritus. Other clinical manifestations include jaundice, cholestatic liver enzymes, antimitochondrial antibodies (AMA), and signs and symptoms of cirrhosis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Approximately 50 to 60 percent of patients with PBC are asymptomatic at diagnosis and are detected because of abnormalities in liver biochemical tests obtained for other reasons. Among patients with symptoms, fatigue and pruritus are most commonly seen (<a class="graphic graphic_table graphicRef50201" href="/z/d/graphic/50201.html" rel="external">table 1</a>). (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The findings on physical examination in patients with PBC vary widely and depend on the stage of the disease at time of presentation. The physical examination is often normal in patients who are asymptomatic. Skin findings are common, such as hyperpigmentation, excoriations, xanthelasmas, and jaundice. Patients may also have hepatosplenomegaly or examination findings suggestive of cirrhosis (<a class="graphic graphic_table graphicRef90943" href="/z/d/graphic/90943.html" rel="external">table 3</a>). (See <a class="local">'Physical examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Common laboratory test abnormalities in patients with PBC included an elevated alkaline phosphatase, AMA, antinuclear antibodies (ANA), and hyperlipidemia. Other findings may include mild elevations in the aminotransferases and an elevated bilirubin level. (See <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with PBC are often diagnosed with other autoimmune disorders, including Sjögren's disease and autoimmune thyroid disease (<a class="graphic graphic_table graphicRef50201" href="/z/d/graphic/50201.html" rel="external">table 1</a>). Musculoskeletal complaints, frequently due to an inflammatory arthropathy, occur in approximately 40 percent of patients with PBC. (See <a class="local">'Associated autoimmune conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications </strong>– Complications of PBC include cirrhosis, hepatocellular carcinoma, metabolic bone disease, and malabsorption. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>PBC should be suspected in patients with an elevated alkaline phosphatase without extrahepatic biliary obstruction, and in females with unexplained itching, fatigue, jaundice, or unexplained weight loss with right upper quadrant discomfort. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">A diagnosis of PBC is established if there is no extrahepatic biliary obstruction and at least two of the following are present (<a class="graphic graphic_algorithm graphicRef140937" href="/z/d/graphic/140937.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An alkaline phosphatase at least 1.5 times the upper limit of normal</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of AMA at a titer of 1:40 or higher (or other PBC-specific autoantibodies [sp100 or gp210], if AMA is negative) (see <a class="local">'Laboratory tests'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histologic evidence of PBC (nonsuppurative destructive cholangitis and destruction of interlobular bile ducts)</p><p></p><p class="bulletIndent1">While a liver biopsy is often not required to make the diagnosis, it provides useful information with regard to staging and prognosis (see <a class="local">'Liver biopsy'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– Several predictive models based upon laboratory and clinical data have been proposed, and two such models (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.globalpbc.com%2Fglobe&amp;token=Gwu1MUQ97eeN9vbOgDEV61OEN5KOKGRXTxjOhhv8xZh2ZDfqH2jjbIN1wJrftDXv&amp;TOPIC_ID=3621" target="_blank">GLOBE score</a> and UK-PBC score) that were developed in the era of UDCA therapy are based on multicenter studies including large cohorts of patients with PBC. (See <a class="local">'Predictive models'</a> above.)</p><p></p><p class="bulletIndent1">Treatment with <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a> has been associated with improved outcomes in patients with PBC. Factors that have been associated with a worse prognosis include presence of symptoms at the time of diagnosis, elevated alkaline phosphatase and bilirubin levels, more advanced histologic stage, presence of ANA, cigarette smoking, and certain genetic polymorphisms. (See <a class="local">'Prognostic factors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335:1570.</a></li><li><a class="nounderline abstract_t">Ludwig J. New concepts in biliary cirrhosis. Semin Liver Dis 1987; 7:293.</a></li><li><a class="nounderline abstract_t">Moebius U, Manns M, Hess G, et al. T cell receptor gene rearrangements of T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis (PBC): oligoclonality of PBC-derived T cell clones. Eur J Immunol 1990; 20:889.</a></li><li><a class="nounderline abstract_t">Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Hepatology 2015; 62:1620.</a></li><li><a class="nounderline abstract_t">Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019; 69:394.</a></li><li><a class="nounderline abstract_t">Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119:1631.</a></li><li><a class="nounderline abstract_t">Sood S, Gow PJ, Christie JM, Angus PW. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology 2004; 127:470.</a></li><li><a class="nounderline abstract_t">Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353:1261.</a></li><li><a class="nounderline abstract_t">Dahlan Y, Smith L, Simmonds D, et al. Pediatric-onset primary biliary cirrhosis. Gastroenterology 2003; 125:1476.</a></li><li><a class="nounderline abstract_t">Lleo A, Battezzati PM, Selmi C, et al. Is autoimmunity a matter of sex? Autoimmun Rev 2008; 7:626.</a></li><li><a class="nounderline abstract_t">Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 2011; 377:1600.</a></li><li><a class="nounderline abstract_t">Peters MG, Di Bisceglie AM, Kowdley KV, et al. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology 2007; 46:769.</a></li><li><a class="nounderline abstract_t">James OF, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 1999; 30:390.</a></li><li><a class="nounderline abstract_t">Myers RP, Shaheen AA, Fong A, et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology 2009; 50:1884.</a></li><li><a class="nounderline abstract_t">Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010; 52:745.</a></li><li><a class="nounderline abstract_t">Balasubramaniam K, Grambsch PM, Wiesner RH, et al. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology 1990; 98:1567.</a></li><li><a class="nounderline abstract_t">Tornay AS Jr. Primary biliary cirrhosis: natural history. Am J Gastroenterol 1980; 73:223.</a></li><li><a class="nounderline abstract_t">Prince MI, Chetwynd A, Craig WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53:865.</a></li><li><a class="nounderline abstract_t">Selmi C, Gershwin ME, Lindor KD, et al. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology 2007; 46:1836.</a></li><li><a class="nounderline abstract_t">Poupon RE, Chrétien Y, Chazouillères O, et al. Quality of life in patients with primary biliary cirrhosis. Hepatology 2004; 40:489.</a></li><li><a class="nounderline abstract_t">Newton JL, Bhala N, Burt J, Jones DE. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol 2006; 44:776.</a></li><li><a class="nounderline abstract_t">Newton JL, Gibson GJ, Tomlinson M, et al. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006; 44:91.</a></li><li><a class="nounderline abstract_t">van Os E, van den Broek WW, Mulder PG, et al. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2007; 46:1099.</a></li><li><a class="nounderline abstract_t">Al-Harthy N, Kumagi T, Coltescu C, Hirschfield GM. The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology 2010; 52:562.</a></li><li><a class="nounderline abstract_t">Jones DE, Bhala N, Burt J, et al. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 2006; 55:536.</a></li><li><a class="nounderline abstract_t">Hollingsworth KG, Newton JL, Taylor R, et al. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol Hepatol 2008; 6:1041.</a></li><li><a class="nounderline abstract_t">Newton JL, Davidson A, Kerr S, et al. Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity. Eur J Gastroenterol Hepatol 2007; 19:125.</a></li><li><a class="nounderline abstract_t">Laurin JM, DeSotel CK, Jorgensen RA, et al. The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol 1994; 89:1840.</a></li><li><a class="nounderline abstract_t">Newton JL, Hollingsworth KG, Taylor R, et al. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology 2008; 48:541.</a></li><li><a class="nounderline abstract_t">Koulentaki M, Ioannidou D, Stefanidou M, et al. Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol 2006; 101:541.</a></li><li><a class="nounderline abstract_t">AHRENS EH Jr, PAYNE MA, KUNKEL HG, et al. Primary biliary cirrhosis. Medicine (Baltimore) 1950; 29:299.</a></li><li><a class="nounderline abstract_t">Mills PR, Skerrow CJ, MacKie RM. Melanin pigmentation of the skin in primary biliary cirrhosis. J Cutan Pathol 1981; 8:404.</a></li><li><a class="nounderline abstract_t">Long RG, Scheuer PJ, Sherlock S. Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology 1977; 72:1204.</a></li><li><a class="nounderline abstract_t">Fleming CR, Dickson ER, Hollenhorst RW, et al. Pigmented corneal rings in a patient with primary biliary cirrhosis. Gastroenterology 1975; 69:220.</a></li><li><a class="nounderline abstract_t">Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1.</a></li><li><a class="nounderline abstract_t">Christensen E, Crowe J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 1980; 78:236.</a></li><li><a class="nounderline abstract_t">Yamazaki K, Nakadate I, Suzuki K, et al. Eosinophilia in primary biliary cirrhosis. Am J Gastroenterol 1996; 91:516.</a></li><li><a class="nounderline abstract_t">Terasaki S, Nakanuma Y, Yamazaki M, Unoura M. Eosinophilic infiltration of the liver in primary biliary cirrhosis: a morphological study. Hepatology 1993; 17:206.</a></li><li><a class="nounderline abstract_t">Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 2001; 60:1046.</a></li><li><a class="nounderline abstract_t">Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003; 98:431.</a></li><li><a class="nounderline abstract_t">Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002; 35:409.</a></li><li><a class="nounderline abstract_t">Yang WH, Yu JH, Nakajima A, et al. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2004; 2:1116.</a></li><li><a class="nounderline abstract_t">Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006; 43:1135.</a></li><li><a class="nounderline abstract_t">Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005; 42:386.</a></li><li><a class="nounderline abstract_t">Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005; 54:528.</a></li><li><a class="nounderline abstract_t">Poupon R, Chazouilleres O, Corpechot C, Chrétien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44:85.</a></li><li><a class="nounderline abstract_t">Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45:118.</a></li><li><a class="nounderline abstract_t">Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194:293.</a></li><li><a class="nounderline abstract_t">Jahn CE, Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985; 89:1266.</a></li><li><a class="nounderline abstract_t">Poupon RE, Ouguerram K, Chrétien Y, et al. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 1993; 17:577.</a></li><li><a class="nounderline abstract_t">Poupon RE, Balkau B, Guéchot J, Heintzmann F. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology 1994; 19:635.</a></li><li><a class="nounderline abstract_t">Nishio A, Keeffe EB, Ishibashi H, Gershwin EM. Diagnosis and treatment of primary biliary cirrhosis. Med Sci Monit 2000; 6:181.</a></li><li><a class="nounderline abstract_t">Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004; 97:397.</a></li><li><a class="nounderline abstract_t">Liu B, Zhang FC, Zhang ZL, et al. Interstitial lung disease and Sjögren's syndrome in primary biliary cirrhosis: a causal or casual association? Clin Rheumatol 2008; 27:1299.</a></li><li><a class="nounderline abstract_t">Tsianos EV, Hoofnagle JH, Fox PC, et al. Sjögren's syndrome in patients with primary biliary cirrhosis. Hepatology 1990; 11:730.</a></li><li><a class="nounderline abstract_t">Hatzis GS, Fragoulis GE, Karatzaferis A, et al. Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren's syndrome. J Rheumatol 2008; 35:2012.</a></li><li><a class="nounderline abstract_t">Crowe JP, Christensen E, Butler J, et al. Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome. Gastroenterology 1980; 78:1437.</a></li><li><a class="nounderline abstract_t">Floreani A, Mangini C, Reig A, et al. Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers. Am J Gastroenterol 2017; 112:114.</a></li><li><a class="nounderline abstract_t">Mayo MJ, Jenkins RN, Combes B, Lipsky PE. Association of clonally expanded T cells with the syndrome of primary biliary cirrhosis and limited scleroderma. Hepatology 1999; 29:1635.</a></li><li><a class="nounderline abstract_t">Culp KS, Fleming CR, Duffy J, et al. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982; 57:365.</a></li><li><a class="nounderline abstract_t">Caramella C, Avouac J, Sogni P, et al. Association between rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 2007; 74:279.</a></li><li><a class="nounderline abstract_t">Mills PR, Rooney PJ, Watkinson G, MacSween RN. Hypercholesterolaemic arthropathy in primary biliary cirrhosis. Ann Rheum Dis 1979; 38:179.</a></li><li><a class="nounderline abstract_t">Gores GJ, Wiesner RH, Dickson ER, et al. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 1989; 96:1552.</a></li><li><a class="nounderline abstract_t">Suzuki A, Lymp J, Donlinger J, et al. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5:259.</a></li><li><a class="nounderline abstract_t">Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308:1.</a></li><li><a class="nounderline abstract_t">Cavazza A, Caballería L, Floreani A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009; 50:1162.</a></li><li><a class="nounderline abstract_t">Trivedi PJ, Lammers WJ, van Buuren HR, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016; 65:321.</a></li><li><a class="nounderline abstract_t">Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 2012; 56:1409.</a></li><li><a class="nounderline abstract_t">Muratori L, Granito A, Muratori P, et al. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis 2008; 12:261.</a></li><li><a class="nounderline abstract_t">Scheuer PJ. Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 1998; 73:179.</a></li><li><a class="nounderline abstract_t">Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379:103.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="4a2f2b3926252c2c23292f0a2f2b3926252c2c23292f642f3f">[email protected]</span>, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67:145.</a></li><li><a class="nounderline abstract_t">Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet 1996; 348:1399.</a></li><li><a class="nounderline abstract_t">Dahlqvist G, Gaouar F, Carrat F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology 2017; 65:152.</a></li><li><a class="nounderline abstract_t">Lazaridis KN, Juran BD, Boe GM, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007; 46:785.</a></li><li><a class="nounderline abstract_t">Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology 2015; 149:1804.</a></li><li><a class="nounderline abstract_t">Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016; 63:930.</a></li><li><a class="nounderline abstract_t">Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123:1044.</a></li><li><a class="nounderline abstract_t">Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20:707.</a></li><li><a class="nounderline abstract_t">Springer J, Cauch-Dudek K, O'Rourke K, et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94:47.</a></li><li><a class="nounderline abstract_t">Jones DE, Al-Rifai A, Frith J, et al. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol 2010; 53:911.</a></li><li><a class="nounderline abstract_t">Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147:1338.</a></li><li><a class="nounderline abstract_t">Locke GR 3rd, Therneau TM, Ludwig J, et al. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996; 23:52.</a></li><li><a class="nounderline abstract_t">Nijhawan PK, Therneau TM, Dickson ER, et al. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 1999; 29:1396.</a></li><li><a class="nounderline abstract_t">Jones DE, Metcalf JV, Collier JD, et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997; 26:1138.</a></li><li><a class="nounderline abstract_t">Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105:2186.</a></li><li><a class="nounderline abstract_t">Mendes F, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Gastroenterol Clin North Am 2008; 37:479.</a></li><li><a class="nounderline abstract_t">Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25:1090.</a></li><li><a class="nounderline abstract_t">Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42:1194.</a></li><li><a class="nounderline abstract_t">Zein CO, Beatty K, Post AB, et al. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology 2006; 44:1564.</a></li><li><a class="nounderline abstract_t">Corpechot C, Gaouar F, Chrétien Y, et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol 2012; 56:218.</a></li><li><a class="nounderline abstract_t">Poupon R, Ping C, Chrétien Y, et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol 2008; 49:1038.</a></li></ol></div><div id="topicVersionRevision">Topic 3621 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8900092" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3324348" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New concepts in biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2112095" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : T cell receptor gene rearrangements of T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis (PBC): oligoclonality of PBC-derived T cell clones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26372460" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30070375" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113084" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology and natural history of primary biliary cirrhosis in a US community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15300579" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16177252" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14598264" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pediatric-onset primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18603021" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Is autoimmunity a matter of sex?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21529926" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17654740" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421645" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Primary biliary cirrhosis once rare, now common in the United Kingdom?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821525" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347176" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Primary biliary cirrhosis: a 2010 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2338193" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7405922" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Primary biliary cirrhosis: natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15138215" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18027862" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Quality of life and everyday activities in patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15368455" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Quality of life in patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16487619" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16800007" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17399846" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20683955" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16299032" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18691944" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17272997" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7942679" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The natural history of abdominal pain associated with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18563843" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16464228" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dermatological manifestations in primary biliary cirrhosis patients: a case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14796348" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6278001" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Melanin pigmentation of the skin in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/870368" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Presentation and course of asymptomatic primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1150026" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pigmented corneal rings in a patient with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2737595" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prognosis in primary biliary cirrhosis: model for decision making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7350046" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633501" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Eosinophilia in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8428717" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Eosinophilic infiltration of the liver in primary biliary cirrhosis: a morphological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602476" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591064" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11826416" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625657" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16628641" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710222" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753539" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16799997" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17187436" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17240380" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4054519" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8477962" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8119688" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208308" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diagnosis and treatment of primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15208427" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18512115" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Interstitial lung disease and Sjögren's syndrome in primary biliary cirrhosis: a causal or casual association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2347546" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sjögren's syndrome in patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18709690" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6768634" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27779196" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10347101" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Association of clonally expanded T cells with the syndrome of primary biliary cirrhosis and limited scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6896227" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Autoimmune associations in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17369071" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Association between rheumatoid arthritis and primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/443887" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hypercholesterolaemic arthropathy in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2785470" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17174610" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6847917" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19585656" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25567117" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504852" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456179" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9473003" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/150690" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28427765" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937278" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Natural history of early primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27688145" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17680647" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261009" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26223498" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12360466" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7930469" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9934730" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800924" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25160979" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8550048" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Time course of histological progression in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10216121" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Incidence of cancer in primary biliary cirrhosis: the Mayo experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9362353" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20502446" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18499032" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Antimitochondrial antibody-negative primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141422" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16250040" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133468" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21703179" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18930330" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Genetic factors of susceptibility and of severity in primary biliary cirrhosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
